What Moderna and Pfizer Vaccines Mean for Stock Market

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Moderna Inc (NASDAQ:MRNA) announced that its vaccine appears to be 94.5% effective. The on-going study is still based on preliminary data, but U.S. sentiment appears high as this is the second major vaccine breakthrough.

This news follows last week’s announcement that Pfizer Inc. (NYSE:PFE) Coronavirus vaccine appeared to be 90% effective.

Both companies are now seeking permission to use within the coming weeks.

Watch the full interview to see if Stay-at-Home stocks are dead or becoming disruptive technologies worthy of further investment.

The largest disruptor of them all is slated to come online as soon as January 2021. A tech revolution that could see growth unseen in the technology industry since the boom of the internet!

Watch my special presentation outlining how you can become an early investor and profit from this history-making event.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.